A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular Outcomes

Conditions

• Diabetes Mellitus, Type 2

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Empagliflozin — DRUG
  new users (initiators) of Empagliflozin
• Liraglutide — DRUG
  initiators of Liraglutide

Study Details

The primary research question is to evaluate whether, among patients with type 2 diabetes mellitus (T2D), initiation of empagliflozin changes the adjusted incidence of outcomes compared with initiation of Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA).

Key Dates

First listed

Jun 20, 2019

Start date

Oct 1, 2018

Status verified

Jun 2023

Primary completion

Jun 16, 2022

Completion

Jun 16, 2022

Study Design

Enrollment

26,774 participants (actual)

Arms

• Arm: Patients with type 2 diabetes

Primary Outcome Measure

Incidence Rate of Expanded Major Adverse Cardiovascular Event (MACE) Composite Outcome - OT Analysis [ Time Frame: From first initiation of empagliflozin or liraglutide until end of follow-up, up to 6 years. ]

Find similar trials

Related Studies

• An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
  Enrolling By Invitation · Novo Nordisk A/S · Morgantown, West Virginia
• Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
  Recruiting · The University of Texas Health Science Center at San Antonio · San Antonio, Texas
• Tau PET Imaging in the Northern Manhattan Study of Metabolism and Mind.
  PHASE2 · Enrolling By Invitation · Columbia University · New York, New York
• Blood Markers of Early Pancreas Cancer
  Recruiting · University of Nebraska · Omaha, Nebraska